2013 Fiscal Year Final Research Report
Development of new tharapy and search for new cell death mechanism in hematologic malignancies
| Project/Area Number |
23390273
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
ADACHI Souichi 京都大学, 医学(系)研究科(研究院), 教授 (10273450)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
WATANABE Ken-itirou 京都大学, 医学研究科, 講師 (20324634)
ITOU Hiroshi 京都大学, 医学研究科, 助教 (20362387)
|
|---|
| Project Period (FY) |
2011-04-01 – 2014-03-31
|
| Keywords | 難治性血液腫瘍 / アポトーシス / オートファジー / 新規予後因子 / 白血病幹細胞 |
|---|
| Research Abstract |
We have done the following three projects to develop new therapies for chemo-resisitant hematologic malignancies. (1) To search new cell death mechanism of refractory leukemia in vivo (2) To search new prognostic factors in refractory leukemia (3) Analyze function of cells in minimal residual disease (MRD) of AML. (1) We detected autophagic cells in bone marrow, liver, spleen and craniospinal system of NOG mouse transplanted Ph1 ALL leukemic cells after treatment of dasatinib. (2) We analysed KIT mutations in AML-05 samples. Event free survivals are poor and relapse rates are high in KIT mutation positive patients. (3) We detected CD56 expression in CD34+CD33+ precursor cells only in Down syndrome patients and not in non-Down syndrome patients. We have to be carefully analyse MRD detection especially in Down syndrome patients.
|
